Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine

被引:17
|
作者
Maier, Sandra B. [1 ]
Huang, Xiao [1 ]
Massad, Eduardo [2 ,4 ]
Amaku, Marcos [2 ]
Burattini, Marcelo N. [2 ,3 ]
Greenhalgh, David [1 ]
机构
[1] Univ Strathclyde, Dept Math & Stat, Glasgow G1 1XH, Lanark, Scotland
[2] Univ Sao Paulo, LIM01 Hosp Clin, Fac Med, Sao Paulo, SP, Brazil
[3] Univ Fed Sao Paulo, Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil
[4] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England
关键词
Dengue; Vaccination; Optimal vaccination age; Age-structured model; Serotype; Risk function; Mortality; Hospitalisation; Mathematical model; ANTIBODY-DEPENDENT ENHANCEMENT; HEMORRHAGIC-FEVER; TRANSMISSION DYNAMICS; YELLOW-FEVER; SAO-PAULO; RISK; DISEASE; PERSISTENCE; SEROTYPES; INFECTION;
D O I
10.1016/j.mbs.2017.09.004
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this paper we study a mathematical model to analyse the optimal vaccination age against Dengue in Brazil. Data from Brazil are used to estimate the basic reproduction numbers for each of the four Dengue serotypes and then the optimal vaccination age is calculated using a method due to Hethcote [1]. The vaccine has different efficacies against each serotype. Vaccination that is too early is ineffective as individuals are protected by maternal antibodies but leaving vaccination until later may allow the disease to spread. First of all the optimal vaccination ages ate calculated where there is just one serotype in circulation and then when there are multiple serotypes. The calculations are done using data both assuming constant vaccine efficacy and age-dependent vaccine efficacy against a given serotype. The multiple serotype calculations are repeated assuming that the first infection is a risky infection and that it is not (to model Dengue Antibody Enhancement). The calculations are then repeated when any third or fourth Dengue infections are asymptomatic, so that two Dengue infections with different serotypes provide effective permanent immunity. The calculations are also repeated when the age-dependent risk function (fitted to Brazilian data) is hospitalisation from Dengue and when it is mortality due to Dengue. We find a wide variety of optimal vaccination ages depending on both the serotypes in circulation and the assumptions of the model. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:15 / 32
页数:18
相关论文
共 50 条
  • [1] Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease
    Lesley J. Scott
    [J]. Drugs, 2016, 76 : 1301 - 1312
  • [2] Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease
    Scott, Lesley J.
    [J]. DRUGS, 2016, 76 (13) : 1301 - 1312
  • [3] EFFECTIVENESS OF A TETRAVALENT DENGUE VACCINE, BRAZIL, 2016-2019
    Luna, Expedito J.
    Riediger, Irina
    Crosewski, Fernanda
    Garrett, Denise
    Moraes, Jose C.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 414 - 414
  • [4] Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
    Vigne, Claire
    Dupuy, Martin
    Richetin, Aline
    Guy, Bruno
    Jackson, Nicholas
    Bonaparte, Matthew
    Hu, Branda
    Saville, Melanie
    Chansinghakul, Danaya
    Noriega, Fernando
    Plennevaux, Eric
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (09) : 2004 - 2016
  • [5] Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans
    Qiao, Ming
    Shaw, David
    Forrat, Remi
    Wartel-Tram, Anh
    Lang, Jean
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2011, 85 (04): : 724 - 731
  • [6] Development of a tetravalent vaccine against dengue
    Guy, Bruno
    Saville, Melanie
    Lang, Jean
    [J]. VIROLOGIE, 2010, 14 (05) : 311 - 321
  • [7] Tetravalent Dengue Vaccine for Children COMMENT
    Balasubramanian, S.
    [J]. INDIAN PEDIATRICS, 2015, 52 (03) : 240 - 240
  • [8] Development of a tetravalent dengue DNA vaccine
    Liew, SC
    Reid, MP
    Aaskov, JG
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2003, 28 : S31 - S32
  • [9] Live attenuated tetravalent dengue vaccine
    Bhamarapravati, N
    Sutee, Y
    [J]. VACCINE, 2000, 18 : 44 - 47
  • [10] Tetravalent Dengue Vaccine in Healthy Children
    Salvana, Edsel M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (18): : 1769 - 1769